PDK1‐stabilized LncRNA SPRY4‐IT1 promotes breast cancer progression via activating NF‐κB signaling pathway

Author:

Zhang Yulu1,Chen Hongling1,Yuan Renjie1,Wang Yange1,Zhang Dian1,Zeng Qian1,Jiang Weiqian2,Zhang Ruiming1,Chen Tingmei1,Chai Chengsen1,Guo Bianqin13

Affiliation:

1. Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine Chongqing Medical University Chongqing China

2. Department of Orthopedics First Affiliated Hospital of Chongqing Medical University Chongqing China

3. Department of Clinical Laboratory Chongqing University Cancer Hospital Chongqing China

Abstract

AbstractPyruvate dehydrogenase kinase 1 (PDK1) is a widely known glycolytic enzyme, and some evidence showed that PDK1 promoted breast cancer by multiple approaches. However, very few lncRNAs have been identified to be associated with PDK1 in breast cancer in previous research. In this study, we found that lncRNA sprouty4‐intron transcript 1 (SPRY4‐IT1) was regulated by PDK1 with correlation analysis, and PDK1 upregulated SPRY4‐IT1 remarkably in breast cancer cells, as PDK1 interacted with SPRY4‐IT1 in the nucleus and significantly enhanced the stability of SRPY4‐IT1. Furthermore, SPRY4‐IT1 was highly expressed in breast cancer, significantly promoted the proliferation and inhibited apoptosis of breast cancer cells. In terms of mechanism, SPRY4‐IT1 inhibited the transcription of NFKBIA and the expression of IκBα, thus promoting the formation of p50/p65 complex and activating NF‐κB signaling pathway, which facilitated survival of breast cancer cells. Therefore, our finding reveals that PDK1/SPRY4‐IT1/NFKBIA axis plays a crucial role that promoting tumor progression, and SPRY4‐IT1 knockdown incombined with PDK1 inhibitor is promising to be a new therapeutic strategy in breast cancer.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3